ANTI-TNF PHARMACOKINETICS AND RESPONSE TO THERAPY IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS (THE ARCH STUDY)

25% of children hospitalized with acute severe ulcerative colitis (ASUC) rescued with infliximab (IFX) at labeled dosing undergo a colectomy prior to discharge. Our aim was to determine whether IFX pharmacokinetics (PK) are associated with treatment response in pediatric ASUC.

This entry was posted in News. Bookmark the permalink.